91 related articles for article (PubMed ID: 25576094)
1. Preferential cytotoxicity of bortezomib toward highly malignant human liposarcoma cells via suppression of MDR1 expression and function.
Hu Y; Wang L; Wang L; Wu X; Wu X; Gu Y; Shu Y; Sun Y; Shen Y; Xu Q
Toxicol Appl Pharmacol; 2015 Feb; 283(1):1-8. PubMed ID: 25576094
[TBL] [Abstract][Full Text] [Related]
2. Targeting sarcoplasmic/endoplasmic reticulum Ca²+-ATPase 2 by curcumin induces ER stress-associated apoptosis for treating human liposarcoma.
Wang L; Wang L; Song R; Shen Y; Sun Y; Gu Y; Shu Y; Xu Q
Mol Cancer Ther; 2011 Mar; 10(3):461-71. PubMed ID: 21282356
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
4. High expression of sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPase 2b blocks cell differentiation in human liposarcoma cells.
Wang L; Li W; Yang Y; Hu Y; Gu Y; Shu Y; Sun Y; Wu X; Shen Y; Xu Q
Life Sci; 2014 Mar; 99(1-2):37-43. PubMed ID: 24508653
[TBL] [Abstract][Full Text] [Related]
5. SBF-1 preferentially inhibits growth of highly malignant human liposarcoma cells.
Chen W; Qian X; Hu Y; Jin W; Shan Y; Fang X; Sun Y; Yu B; Luo Q; Xu Q
J Pharmacol Sci; 2018 Dec; 138(4):271-278. PubMed ID: 30415825
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
[TBL] [Abstract][Full Text] [Related]
7. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Piva R; Ruggeri B; Williams M; Costa G; Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M; Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P; de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G
Blood; 2008 Mar; 111(5):2765-75. PubMed ID: 18057228
[TBL] [Abstract][Full Text] [Related]
8. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
Escalante AM; McGrath RT; Karolak MR; Dorr RT; Lynch RM; Landowski TH
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1567-76. PubMed ID: 23572175
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
Nawrocki ST; Carew JS; Dunner K; Boise LH; Chiao PJ; Huang P; Abbruzzese JL; McConkey DJ
Cancer Res; 2005 Dec; 65(24):11510-9. PubMed ID: 16357160
[TBL] [Abstract][Full Text] [Related]
10. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.
Fels DR; Ye J; Segan AT; Kridel SJ; Spiotto M; Olson M; Koong AC; Koumenis C
Cancer Res; 2008 Nov; 68(22):9323-30. PubMed ID: 19010906
[TBL] [Abstract][Full Text] [Related]
11. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
12. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Yu C; Rahmani M; Dent P; Grant S
Exp Cell Res; 2004 May; 295(2):555-66. PubMed ID: 15093752
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells.
Harati K; Daigeler A; Hirsch T; Jacobsen F; Behr B; Wallner C; Lehnhardt M; Becerikli M
Int J Mol Med; 2016 Jun; 37(6):1535-41. PubMed ID: 27082154
[TBL] [Abstract][Full Text] [Related]
14. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Tang ZY; Wu YL; Gao SL; Shen HW
J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
16. The combination of proteasome inhibitors bortezomib and gambogic acid triggers synergistic cytotoxicity in vitro but not in vivo.
Liu N; Huang H; Xu L; Hua X; Li X; Liu S; Yang C; Zhao C; Zhao C; Li S; Dou QP; Liu J
Toxicol Lett; 2014 Jan; 224(3):333-40. PubMed ID: 24291039
[TBL] [Abstract][Full Text] [Related]
17. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
